Ricardo Tosto and Why Transparency in the Legal Practice in Brazil Is Important

It’s no secret that Brazil is a repository of brilliant, talented and impartial lawyers who serve the public with the best of their ability. However, it can’t be denied that there could be lawyers who are surreptitious about their wealth and their tax obligations that they have to pay to the government. They have to reveal and declare such assets, especially if they live overseas, if only because it’s the only way that the government can sustain its funding for different social causes. One of the few exuberant lawyers today who are valiant and courageous enough to deal with such issue in transparency in the legal practice is Ricardo Tosto.

The Law 13, 254

The good thing right now in Brazil is that there is already a law that sort of forces lawyers to divulge their tax obligations. As the founding partner of Milk and the law firm Tosto and Barros, Ricardo sees it his duty to enforce the law so that the lawyers overseas can give the support that he needs to push for such advocacy. Despite the possible respite that he could be facing from his fellow lawyers, Ricardo Tosto seems to have the sense of humor and levity to deal with the issue in the most friendly and yet assertive manner.

With such law, it would now be easier for people like Ricardo Tosto to get the lawyers overseas to reveal their hidden assets, resources, and digital money, and pay the right fees that warrant such level of wealth. Better Partnerships

Why should the society and other lawyers care about such tax obligations? Ricardo Tosto believes that in order to build healthy technical partnerships between overseas clients and local ones, the involvement of the National Government with its intervention should enforce a legal mechanism for transparency. No other form of transparency system exists out there that seems to be better than the Law 13,254, which regulates how the tax regulation is done among lawyers in Brazil.

About Ricardo Tosto

Other than being the advocate for transparency, Ricardo Tosto is known to be the creator of Milk, which is a platform that offers creative solutions for lawyers to increase their productivity.

Follow Ricardo

Jeff S. Aronin: A Leader in Global Biopharmaceuticals

Jeff S. Aronin states, “Problems people have deemed unsolvable are the problems we are solving.” That philosophy is the guiding principle of Paragon Biosciences, a biopharmaceutical investment firm and global leader in healthcare development. Diseases, and more importantly, diseases that have no known treatment, impede a person’s quality of life. More than 6,000 known diseases do not have a drug treatment plan to mitigate the disease by either lessening the severity of the symptoms or decreasing the pain associated with the disease. Jeff S. Aronin and Paragon Biosciences are committed to improving the lives of patients by investing in innovative biotechnology companies (http://chicago.blueskyinnovation.com/vault/network/aronin-jeff/). Starting with the needs of patients and through innovation and cutting-edge technology, Jeff S. Aronin and his team invest in companies that develop drugs to combat diseases that do not currently have a treatment plan available.

There are four companies under the portfolio of Paragon Biosciences. Castle Creek Pharmaceuticals focuses on treatments for persons living with dermatologic conditions that are rare, serious or debilitating. Seeking innovative treatment for patients living with diseases of the central nervous system is Harmony Biosciences. Decade is an R&D company focusing on identifying treatment for Alzheimer’s disease and Precision BP works on the development of treatments for those living with rare genetic oncology diseases.

The success of Paragon Biosciences in meeting the needs of patients is dependent upon a team passionate about improving the quality of life of those living with diseases for which there is no available treatment. Jeffery S. Aronin, the chairman and CEO of Paragon Biosciences head this team of innovative leaders. Mr. Aronin has been involved as president and chief executive officer in biopharmaceuticals since 2000 and he has served as the chairman and CEO of Paragon Biosciences since 2010. In addition to being a transformational leader, Jeff also has considerable expertise in strategic and business development including mergers and acquisitions, as well as finance and brand marketing.